GB-Products-Premium-DataArticle (Tableau): Generics Bulletin’s Top 50 Ranking For 2024

Compiling All The Data From Our List Of The Leading Generics And Biosimilars Firms

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

Product Launch Abstract
Lupin Hopes The Spiriva Generic Launch Will Boost Its Fortunes • Source: Shutterstock

This week has seen Generics Bulletin publish its annual Top 50 ranking for 2024 of the leading companies across the generics and biosimilars industry.

Across three separate articles, we showed how the global top ten companies are seeing change, despite remaining a stable leading...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C13

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C12

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

More from Value Added Medicines

GB-Products-Premium-DataArticle (Tableau): Generics Bulletin’s Top 50 Ranking For 2024

 
• By 

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.